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Neuroendocrine tumors are rare tumors primarily located in the gastrointestinal tract. Goblet cell carcinoid is a rare subgroup
of neuroendocrine tumors located in the appendix. Neuroﬁbromatosis type 1 is an autosomal dominant disorder caused by a
mutation in the NF1 gene. Patients with neuroﬁbromatosis type 1 have an increased incidence of typical neuroendocrine tumors,
but it is unknown if this is the case with goblet cell carcinoids. We describe a patient with both neuroﬁbromatosis type 1 and goblet
cell carcinoid, that according to literature would occur in 0.00017 per million per year. This may suggest a previously unknown
association between neuroﬁbromatosis type 1 and goblet cell carcinoids.
1.Introduction
Neuroendocrine tumors (NETs) are rare with an estimated
prevalence of 35/100.000 per year [1]. The most frequent
location of NETs is the gastrointestinal tract where most
originate from enterochromaﬃn (EC) cells [2, 3]. These
cells originate from the neural crest and constitute the
diﬀuse neuroendocrine system. Goblet cell carcinoid (GCC)
tumors are a very rare subgroup of mucin producing NETs
usually arising in the appendix. The incidence of GCCs
is approximately 0.5 per million/year [4]. In contrast to
other NETs, GCCs have a mixed phenotype with partial
neuroendocrine diﬀerentiation and partial intestinal type
goblet cell morphology [5].
Neuroﬁbromatosis type 1 (NF1) is an autosomal dom-
inant inherited disorder with an estimated prevalence of
1/3.000 [6]. NF1 is characterised by multiple caf´ ea ul a i t
spots, axillary and inguinal freckling, cutaneous neuroﬁ-
bromas, and hamartomas of the iris. Learning disabilities
are seen in more than half of the aﬀected individuals.
Less common, but potentially more harmful manifestations
are plexiform neuroﬁbromas, optic tumors, gliomas in the
central nervous system, vasculopathy, and an increased risk
of malignancies. The disease is caused by heterozygote loss-
of-functionmutationsintheNF1gene,andmorethanhalfof
all patients have de novo germ line mutations. For unknown
reasons the mutation rate for the NF1 gene is among the
highest observed. The function of the protein neuroﬁbromin
is not fully known, but it is a multidomain molecule with
the capacity to regulate several intracellular processes such
as RAS-cyclic AMP and ERK/MAP kinase cascades. Thus, it
f u n c t i o n sa sat u m o rs u p p r e s s o rg e n e .T h ed e v e l o p m e n to f
tumors, caf´ e au lait spots, and neuroﬁbromas is caused by
spontaneous somatic mutations in the one remaining intact
NF1geneleavingthesecellsunabletoexpressneuroﬁbromin.
Thereby, the disease becomes progressive throughout life,
and the rate of spontaneous somatic mutation determines
the severity of disease manifestations as well as the risk of
cancers in tissues of neuroectodermal origin. Consequently,
NF1 is associated with ordinary NETs, especially those
located in the periampullary region [7, 8].
It is unknown whether an association exists between NF1
and GCC. In the following we describe a patient with both
diseases.2 Case Reports in Gastrointestinal Medicine
Figure 1: Histopathological examination. (A) Goblet cell carcinoid composed of cells with signet ring cells appearance with varied dilated
cytoplasm due to mucin production with displacement of the nuclei to the periphery of the neuroendocrine cells location in the cytoplasm
(HE, ×200); ((B) and (C)) positive staining for chromogranin A (B) and synaptophysin (C) demonstrating neuroendocrine diﬀerentiation
(×200); (D) mucin stain (Alcian Blue, ×200).
2. Patient
A 60-year-old woman with known NF1 displaying the
classical features including multiple neuroﬁbromas was
admitted with signs of acute appendicitis. She presented
lower right-sided abdominal pain, distended abdomen, and
elevated infection parameters and underwent laparoscopic
appendectomy. She was in good health until the appendicitis
and had never experienced any carcinoid symptoms. Besides
an inﬂammatory aﬀected appendix the pathology report
showed a tumor with multiple inﬁltrating microglandular
elements of goblet cells with signet ring cell features
appearing as a goblet cell carcinoid subtype B (Figure 1(A)).
The diagnosis of a goblet cell carcinoid was conﬁrmed by
positive immunostaining for the neuroendocrine markers
chromogranin A (CgA) (Figure 1(B)) and synaptophysin
(Figure 1(C)). Further, mucin was seen in Alcian blue-
stained slides (Figure 1(D)). Proliferation index showed a
Ki67 index of 30–40%. There was no sign of extension
throughout the appendix wall but the resection margins
were positive. Therefore, a right-sided hemicolectomy was
performed with free margins and no lymph node metastases.
Serologically,tumormarkersserotoninandCgAwereslightly
increased while urinary 5-HIAA, carcinoembryonic antigen
(CEA), cancer antigen 19-9 (CA 19-9), and cancer antigen
125 (CA 125) were all normal after surgery. Computer
tomography (CT) scan showed no signs of metastases in
the abdomen or thorax, which indicates the cancer has been
radically resected. The somatostatin receptor scintigraphy
w a sn e g a t i v ea se x p e c t e d[ 9].
3. Discussion
To the best of our knowledge this is the ﬁrst report of a
patient with GCC and NF1. The majority of GCC patients
present in their ﬁfth or sixth decades [10] with a slight
female preponderance [11, 12]. Though the combination
of NF1, and GCC could be coincidental both conditions
are rare, and the expected chance of having both is
approximately 0.00017 per million/year. As goblet cells
derive of neuronal ectoderm, they are likely to express
neuroﬁbromin. Thereby, they may have an increased tumor
risk with a biallelic haploinsuﬃciency of NF1 gene. This
would be in line with the association between NF1 and other
NETs.
Usually, GCCs stain scattered positively for the neuroen-
docrine markers chromogranin A and synaptophysin but
similar to the present case, they also produce mucin like
colorectal adenocarcinomas [13]. Only a few GCCs have
somatostatin receptors and somatostatin receptor scintig-
raphy for diagnosis, and staging is usually negative. The
standard NET markers chromogranin A, serotonin, and U-
5HIAAareusuallynormaloronlyslightlyincreased.Though
present in more than 50% of patients with small intestinal
NET [14], the carcinoid syndrome including diarrhoea and
ﬂushing is absent in patients with GCC. Followup after
GCC is a clinical challenge and will usually include regular
CT/MRIimagingcombinedwithbloodtestsforCEA,CA19-
9, and CA 125. The latter may be elevated in some patients
andserveasatumormarker.Ifrecurrenceissuspected,FGD-
PET may be of value [9].
MostGCCsarelocalizedatthetimeofdiagnosisandhave
a good prognosis with overall 5-year survival of 75% [10].
GCCs are signiﬁcantly more malignant than typical NETs
both of the appendix and in general [11, 15] with less than
20% median 5-year survival in disseminated disease [10].
This is the ﬁrst case of GCC in an NF1 patient. The
treatment of GCC in NF1 should not diﬀer from other
GCC patients as it includes appendectomy and right-sided
hemicolectomy with lymph node dissection. GCC frequently
metastasizes to the ovaries but routine hysteronsalpingo-
oophorectomy is only recommended in the presence of
ovarian metastases. In metastatic disease peritonectomy and
intraoperative chemotherapy may be an option, and the
use of chemotherapy follows the principles for treatment of
colorectal adenocarcinoma [9, 16].
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